Back to Screener

Healthcare

Smith & Nephew plc(SNNUF)

Live Price

Offline

$15.10

+1.27% today

1Y Change

+2.75%

Window

Jun 20, 2025 โ†’ Jun 16, 2026

Market Cap
$13.28B
Revenue Growth
+8.5%
EPS Growth
+57.4%
Dividend Yield
2.5%

Coverage: 248 bars ยท Jun 20, 2025 โ†’ Jun 16, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Smith & Nephew plc (SNNUF) is a Healthcare stock with a market cap of $13.28B and listed on OTC. The stock last traded around $15.10 and up 2.8% across the available one-year price window (Jun 20, 2025 โ†’ Jun 16, 2026). Baseline metrics include revenue growth of +8.5%, EPS growth of +57.4%, a dividend yield of 2.5%. What stands out right now is revenue +8.5%, EPS +57.4%, free cash flow +43.7% with operating margin 16.3% and ROIC 9.1%. The dividend matters to the case here, with a current yield around 2.5%. Valuation is more restrained than many high-expectation growth names at P/E 21.2 and price/sales 2.1. Stock Foundry combines SNNUF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

SNNUF

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

SNNUF Max Drawdown

-20.32%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for SNNUF and SPY.

Calendar-year return history is still loading or unavailable.

Financial profile

Smith & Nephew plc (SNNUF)

Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.

FY Revenue

$5.2B

-0.1% YoY

FY Net Income

$524.0M

+135.0% YoY

Free Cash Flow

$469.0M

+326.4% YoY

Revenue Growth

+8.5%

EPS Growth

+57.4%

Gross Margin

68.0%

Net Margin

10.1%

Income statement

USD

Annual
Metric20252024202320222021
Revenue6.3B5.8B5.5B5.2B5.2B
Gross Profit4.3B4.0B3.8B3.7B3.7B
Operating Income1.0B657M425M450M593M
EBITDA1.6B1.2B956M986M1.2B
Net Income639M412M263M223M524M
EPS (Diluted)โ€”โ€”โ€”โ€”โ€”

Balance sheet

USD

Point-in-time
Metric20252024202320222021
Cash & Equivalents558M619M302M350M1.3B
Total Assets10.5B10.4B10.0B10.0B10.9B
Total Liabilities5.2B5.1B4.8B4.7B5.4B
Shareholder Equity5.3B5.3B5.2B5.3B5.6B
Total Debt3.3B3.3B3.1B2.9B3.3B
Net Debt2.8B2.7B2.8B2.5B2.0B

Cash flow positioning

Latest Full Year

Operating Cash Flow

877M

+87.4% YoY

Capital Expenditures

408M

-14.0% YoY

Free Cash Flow

469M

+326.4% YoY

Key ratios

  • Gross Margin

    68.0%

  • Operating Margin

    16.3%

  • Net Margin

    10.1%

  • ROE

    11.8%

  • Debt / Equity

    0.63x

Next Step

Turn financials into a decision

Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.